Key Points
- Director John Paganelli bought 10,000 shares at about $1.14 on March 20 for $11,400, increasing his holding to 394,340 shares (a 2.6% rise) as disclosed in an SEC filing.
- OPKO reported Q results showing an EPS of ($0.04) that beat estimates, but revenue fell 19.1% year‑over‑year to $148.5M and the company still has negative net margin (37.19%) and ROE, with analysts forecasting about –0.25 EPS for the year.
- Analyst sentiment is mixed-to-negative: the average rating is Hold with an average price target of $2.03, Barrington trimmed its target to $1.50 (but kept a Buy), Weiss Ratings has a sell (D‑) rating, and institutional investors own roughly 64.6% of the stock.
OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) Director John Paganelli bought 10,000 shares of OPKO Health stock in a transaction on Friday, March 20th. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $11,400.00. Following the acquisition, the director owned 394,340 shares in the company, valued at $449,547.60. The trade was a 2.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
OPKO Health Price Performance
Shares of OPK opened at $1.12 on Friday. OPKO Health, Inc. has a 52 week low of $1.10 and a 52 week high of $1.83. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. The firm has a market cap of $850.16 million, a price-to-earnings ratio of -3.73 and a beta of 1.50. The stock has a 50 day moving average of $1.23 and a 200-day moving average of $1.34.
OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The business had revenue of $148.50 million for the quarter, compared to analyst estimates of $139.76 million. During the same period in the prior year, the company posted $0.01 EPS. The business's revenue was down 19.1% compared to the same quarter last year. As a group, analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.
Wall Street Analyst Weigh In
OPK has been the topic of a number of recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of OPKO Health in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Finally, Barrington Research dropped their price objective on shares of OPKO Health from $2.25 to $1.50 and set an "outperform" rating on the stock in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, OPKO Health currently has an average rating of "Hold" and an average price target of $2.03.
Get Our Latest Stock Report on OPKO Health
Institutional Investors Weigh In On OPKO Health
Several large investors have recently added to or reduced their stakes in the stock. World Investment Advisors lifted its stake in OPKO Health by 63.8% in the fourth quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company's stock valued at $84,000 after buying an additional 25,902 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of OPKO Health by 1,056.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 35,841 shares during the last quarter. Virtu Financial LLC bought a new position in shares of OPKO Health during the fourth quarter worth about $145,000. EP Wealth Advisors LLC acquired a new stake in shares of OPKO Health in the 4th quarter worth about $37,000. Finally, XTX Topco Ltd acquired a new stake in shares of OPKO Health in the 4th quarter worth about $432,000. 64.63% of the stock is owned by institutional investors and hedge funds.
Key OPKO Health News
Here are the key news stories impacting OPKO Health this week:
- Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his holding to 394,340 shares — insider buying can signal management confidence and provide short-term support for the stock. SEC Filing
- Positive Sentiment: Barrington Research kept a Buy rating on OPK (supportive stance), which may sustain interest from growth/penny-stock investors despite a lower price target. Barrington Article
- Neutral Sentiment: Zacks published a thematic note discussing OPK's strengths (RAYALDEE sales, partnerships) but flagged revenue declines and concentration risk — useful context for longer-term holders assessing risk/reward. Zacks Hold Article
- Negative Sentiment: Zacks Research sharply cut near‑term EPS forecasts across multiple quarters and fiscal years (many quarterly estimates moved to roughly $(0.07)–$(0.08); FY2026 and FY2027 estimates were lowered to about $(0.29)). The downgrade signals weaker expected profitability and raises the bar for OPK to deliver operational improvements — a primary driver of the stock’s downward move today.
- Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50. Even though the firm kept a Buy rating, the lower target reduces upside expectations and can pressure sentiment among short‑term traders. InsiderMonkey Article
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
